	US 11,897,941 B2
	Compositions and methods for reducing bacterial aggregation
Begona Heras, Victoria (AU); Jason Paxman, Victoria (AU); Mark Schembri, Queensland (AU); and Alvin Lo, Victoria (AU)
Assigned to La Trobe University, Bundoora (AU); and The University of Queensland, St. Lucia (AU)
Filed by La Trobe University, Bundoora (AU); and The University of Queensland, St. Lucia (AU)
Filed on Feb. 22, 2021, as Appl. No. 17/181,491.
Application 17/181,491 is a continuation of application No. PCT/AU2019/050893, filed on Aug. 23, 2019.
Claims priority of application No. 2018903096 (AU), filed on Aug. 23, 2018.
Prior Publication US 2021/0292397 A1, Sep. 23, 2021
Int. Cl. C07K 16/12 (2006.01); A61P 31/04 (2006.01); A01N 63/50 (2020.01); A61K 39/40 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/1232 (2013.01) [A01N 63/50 (2020.01); A61K 39/40 (2013.01); A61K 45/06 (2013.01); A61P 31/04 (2018.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)]

14 Claims

1. An isolated antibody or antigen binding fragment thereof comprising:

a) a CDRH1 comprising the sequence set forth in SEQ ID NO: 3;

a CDRH2 comprising the sequence set forth in SEQ ID NO: 4;

a CDRH3 comprising the sequence set forth in SEQ ID NO: 5;

a CDRL1 comprising the sequence set forth in SEQ ID NO: 6;

a CDRL2 comprising the sequence set forth in SEQ ID NO: 7; and

a CDRL3 comprising the sequence set forth in SEQ ID NO: 8; or

b) a CDRH1 comprising the sequence set forth in SEQ ID NO: 15;

a CDRH2 comprising the sequence set forth in SEQ ID NO: 16;

a CDRH3 comprising the sequence set forth in SEQ ID NO: 17;

a CDRL1 comprising the sequence set forth in SEQ ID NO: 18;

a CDRL2 comprising the sequence set forth in SEQ ID NO: 19; and

a CDRL3 comprising the sequence set forth in SEQ ID NO: 20.